SEQTOR-Study
Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs
II
Status: Rekrutierung beendet
Zeitraum
2014
2018
Zentren
Keine Zentren gesucht
Patienten
180
108
14.04.2022
Identifier
AIO-NET-0215/ass
Kontakt
Leitung
Prof. Dr. Marianne Pavel
Ansprechpartner*in
Prof. Dr. Marianne Pavel
Telefon +49 30 450553022
E-Mail marianne.pavel@charite.de